- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
Seeking Alpha / 33 minutes ago 1 Views
Seeking Alpha / 33 minutes ago 1 Views
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation
Comments